Panagiotis Fidias, MD
Medical Oncology · Exeter, NHNPI 1396735585
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 53.6% of the total.
Across 6 payments — averaging $76.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$245
- Seagen Inc.$100
- Johnson & Johnson$65
- Pfizer$47
Across 5 payments — averaging $7056.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
What the payments were for
- Consulting fees$24554%
- Education$21246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 1 | $245 |
| Seagen Inc. | 1 | $100 |
| Johnson & Johnson | 1 | $65 |
| Pfizer | 3 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GILOTRIF$245
How this compares
$457 in reported general payments places this provider in the 55th percentile of 20 medical oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 49 | $1,594 |
| Dexamethasone | 14 | $214 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $175 |
| Levofloxacin | 11 | $162 |
| Oxycodone Hcl | 18 | $135 |
| Prochlorperazine Maleate | 14 | $120 |
| Prednisone | 30 | $100 |
| Mirtazapine | 15 | $95 |
| Lorazepam | 18 | $55 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Exeter
- Peter KaufmanLebanon$651K
- James RigasLebanon$251K
- Tyler CurielLebanon$29K
- Charles GaulinLebanon$20K
- Linda VahdatLebanon$20K
- Barbara CivielloDover$11K
- Jakow DienerBethlehem$1K
- Tara KaufmannLebanon$656
- Hilal HachemLebanon$368
- Cherif AbdelmalekNashua$281
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.